Angioedema due to angiotensin-converting enzyme inhibitors.

[1]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[2]  B. Stricker,et al.  ACE Inhibitor-Induced Angioedema , 1998, Drug safety.

[3]  K. Cooper,et al.  Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. , 1997, Archives of dermatology.

[4]  N. Brown,et al.  Recurrent angiotensin-converting enzyme inhibitor-associated angioedema , 1997 .

[5]  V. Bandi,et al.  Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome , 1997, Intensive Care Medicine.

[6]  J. Bosmans,et al.  An adverse reaction to angiotensin-converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency. , 1997, The Journal of allergy and clinical immunology.

[7]  A. Black,et al.  Angiotensin–converting enzyme (ACE) inhibitors and angio–oedema , 1997, The British journal of dermatology.

[8]  W A Ray,et al.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema , 1996, Clinical pharmacology and therapeutics.

[9]  K. Gregory,et al.  Angioedema of the Intestine , 1996 .

[10]  M. Cicardi,et al.  Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. , 1996, Immunopharmacology.

[11]  J. Nussberger,et al.  Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. , 1994, Clinical science.

[12]  M. Cicardi,et al.  Contraindications to the use of ace inhibitors in patients with C1 esterase inhibitor deficiency. , 1991, The American journal of medicine.

[13]  M. Anderson,et al.  Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. , 1990, The Journal of allergy and clinical immunology.

[14]  W. Inman,et al.  Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. , 1988, JAMA.

[15]  B. Lämmle,et al.  Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. , 1986, Blood.

[16]  R. Colman,et al.  Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. , 1983, The New England journal of medicine.

[17]  E. Erdos,et al.  An enzyme in human blood plasma that inactivates bradykinin and kallidins. , 1962, Biochemical pharmacology.

[18]  W. Müller-Esterl,et al.  Rapid Direct Determination of Low and High Molecular Weight Kininogen in Human Plasma by Particle Concentration Fluorescence Immunoassay (PCFIA) , 1997, Thrombosis and Haemostasis.